Celcuity Inc. announced that the first patient has been dosed in its Phase 1b/2 study (CELC-G-201) evaluating gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). Gedatolisib, the company?s lead therapeutic candidate, is a potent, reversible dual inhibitor that selectively targets all Class 1 PI3K isoforms and mTORC1/2. In August 2023, Celcuity announced that it had entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa® (darolutamide) to Celcuity at no cost for the Phase 1b/2 trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.79 USD | +5.74% |
|
+11.65% | +28.96% |
Jul. 01 | Celcuity Inc.(NasdaqCM:CELC) added to Russell 3000 Growth Index | CI |
Jul. 01 | Celcuity Inc.(NasdaqCM:CELC) added to Russell Microcap Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.96% | 624M | |
+20.63% | 126B | |
+24.16% | 27.95B | |
-20.17% | 20.5B | |
-16.06% | 17.12B | |
-18.07% | 16.1B | |
-47.70% | 14.97B | |
+11.92% | 14.84B | |
+58.32% | 14.38B | |
+149.98% | 12.37B |
- Stock Market
- Equities
- CELC Stock
- News Celcuity Inc.
- Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer